methylglyoxal bis(cyclopentylamidinohydrazone)

05/01/1999 - "Growth inhibition of human osteosarcoma HuO9 cells by methylglyoxal bis(cyclopentylamidinohydrazone) in vitro and in vivo."
07/01/1997 - "The results presented here suggest that in addition to reducing the growth rates, MGBCP can induce apoptotic cell death in three human osteosarcoma cell lines."
05/01/1995 - "The growth of these cultured osteosarcoma cells was inhibited by MGBCP in a dose-dependent manner. "
09/01/1996 - "In the present study, the effects of polyamine depletion by MGBCP on the cell cycle progression in these osteosarcoma cell lines were investigated by flow cytofluormetric analysis. "
09/01/1996 - "These findings suggest that MGBCP suppresses the cell cycle progression in osteosarcoma MG-63, G-292 and HOS cells by inhibiting intracellular polyamine biosynthesis."

06/01/1998 - "Involvement of apoptosis and cyclin D1 gene repression in growth inhibition of T-47D human breast cancer cells by methylglyoxal bis(cyclopentylamidinohydrazone)."
03/01/1998 - "The results presented here suggest that, in addition to reducing the growth rate, MGBCP can induce apoptotic cell death in MRK-nu-1 human breast cancer cells by the reduction of intracellular concentrations of polyamines."
03/01/1998 - "We have investigated the antiproliferative effects of a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone) (MCBCP), on human breast cancer MRK-nu-1 cells. "
06/01/1998 - "In this study, effects of methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP), a potent inhibitor of the polyamine biosynthetic pathway, on the growth and cell cycle of T-47D human breast cancer cells were investigated. "
03/01/1998 - "Apoptosis induction in human breast cancer MRK-nu-1 cells by a polyamine synthesis inhibitor, methylglyoxal bis(cyclopentylamidinohydrazone)(MGBCP)."

05/01/1999 - "In in vivo experiments MGBCP (20 or 50 mg/kg) inhibited the growth of transplanted HuO9 tumors in mice. "
09/01/1996 - "Mitotic indexes (MIs) in these MGBCP-inhibited tumor cells were also decreased. "
09/01/1996 - "MGBCP arrested the tumor cells at the G1 phase by preventing the G/S phase transition. "
03/01/1998 - "MGBCP inhibited tumor growth of MRK-nu-1 cells in a dose-dependent manner as the polyamine contents in the cells decreased. "
07/01/1991 - "The combination of MGBCP and cepharanthine resulted in a greater suppression of macromolecule synthesis in the cells that might have caused the greater suppression of tumor cell growth."

03/01/1994 - "Dioxopiperazine derivative potentiates antitumor effect of methylglyoxal bis(cyclopentylamidinohydrazone) on human and mouse leukemia cells."
07/01/1991 - "Cepharanthine potentiates the antitumor effect of methylglyoxal bis (cyclopentylamidinohydrazone) on human leukemia cells."
04/15/1989 - "MGBCP inhibited the growth of human leukemia Molt 4B and K 562 cells at 10 to 100 microM concentrations. "
04/15/1989 - "Antitumor effect of a new multienzyme inhibitor of polyamine synthetic pathway, methylglyoxal-bis(cyclopentylamidinohydrazone), against human and mouse leukemia cells."

06/01/2000 - "MGBCP (20 mg/kg) was administered intraperitoneally every day for 4 weeks and demonstrated strong inhibitory effects on bone metastases. "
06/01/2000 - "MGBCP inhibited angiogenesis in the transplanted bone and the growth of B16 melanoma cells, thus suggesting a preventive mechanism in bone metastasis. "
06/01/2000 - "A polyamine synthesis inhibitor, methylglyoxal-bis(cyclopentylamidinohydrazone) MGBCP, was investigated for its inhibitory effects on bone metastases. "